Befesa S.A.

  • WKN: A2H5Z1
  • ISIN: LU1704650164
  • Land: Luxemburg

Nachricht vom 01.07.2021 | 08:59

DGAP-DD: Befesa S.A. english


Befesa S.A.: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
01.07.2021 / 08:59
The issuer is solely responsible for the content of this announcement.

/

PUBLICATION PURSUANT TO ARTICLE 19(3) OF REGULATION (EU) No. 596/2014 (MAR)

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1 July 2021

1. Details of the person discharging managerial responsibilities/person closely associated
a Name Helmut Wieser
 
2. Reason for the notification
a Position / status Member of the Board of Directors
b Initial notification / amendment Initial notification
 
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a Name Befesa S.A.  
b LEI 222100VXGA8L6J4ZWG61  
 
4. Details of the transaction(s)
section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a Description of the financial instrument, type of instrument Shares
  Identification code7 LU1704650164
b Nature of the transaction Purchase of shares
c Price(s) and volume(s) Price per share Volume
€57.90 803
d Aggregated information  
- Aggregated volume 803 shares  
- Price €57.90 per share
e Date of the transaction 17 June 2021
f Place of the transaction XETRA
 

 

Company information
Befesa S.A.
46, Boulevard Grande-Duchess Charlotte
L-1330 Luxembourg, Grand Duchy of Luxembourg

LEI: 222100VXGA8L6J4ZWG61 ISIN: LU1704650164

Contact: Rafael Pérez

Email: irbefesa@befesa.com Internet: www.befesa.com



01.07.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Bio-Gate AG

Original-Research: Bio-Gate AG (von GBC AG): Kaufen

02. Dezember 2021